ACT Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

ACT Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-466,000	Closed	-$8.18M	–	120
2021 Q3	$8.18M	Buy	466,000 +1,000	+0.2%	+$11.7K	4.24%	5
2021 Q2	$4.51M	Buy	+465,000	New	+$4.38M	2.32%	7

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

ACT Capital Management's TRIL Position: Q4 2021 in Review

ACT Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 466,000 shares — an estimated $8.18M sold.

ACT Capital Management first reported a position in TRIL in Q2 2021 and held it in 2 quarters. The position peaked at $8.18M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

ACT Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
ACT Capital Management sold 466,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $8.18M.
ACT Capital Management first reported a position in Trillium Therapeutics Inc. in Q2 2021 and held it in 2 quarters.
ACT Capital Management's Trillium Therapeutics Inc. position peaked at $8.18M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.